Serum CA19-9 and CEA levels, Serum CAT, GSH, oxidized glutathione levels , 8-dihidro-2′-deoxiguanosina and F2-Isoprostanes levels in colorectal cancer patients with Lactobacillus: A randomized double-blind controlled trial

  • Shiru Chen Department of Digestive Minimally Invasive Diagnosis and Treatment, The First Affiliated Hospital of Heilongjiang University of Traditional Chinese Medicine, Harbin, Heilongjiang 150000, China.
  • Weili Ning 2. Heilongjiang University of Traditional Chinese Medicine, Harbin, Heilongjiang 150000, China
  • Jiye Zhang 1. Department of Digestive Minimally Invasive Diagnosis and Treatment, The First Affiliated Hospital of Heilongjiang University of Traditional Chinese Medicine, Harbin, Heilongjiang 150000, China
  • Zhenting Wu Department of Digestive Minimally Invasive Diagnosis and Treatment, The First Affiliated Hospital of Heilongjiang University of Traditional Chinese Medicine, Harbin, Heilongjiang 150000, China.
  • Hang Zhou 1. Department of Digestive Minimally Invasive Diagnosis and Treatment, The First Affiliated Hospital of Heilongjiang University of Traditional Chinese Medicine, Harbin, Heilongjiang 150000, China.
  • Ying Liu First Affiliated Hospital of Heilongjiang University of Chinese Medicine in Harbin
DOI: https://doi.org/10.5937/jomb0-56528
Keywords: Lactobacillus, colorectal cancer, oxidative stress, p38 MAPK, JNK, NRF2

Abstract


Background: Oxidative stress (OS) plays a crucial role in colorectal cancer (CRC) progression. Lactobacillus has been proposed as a potential modulator of OS. This randomized controlled trial aimed to evaluate the effects of Lactobacillus supplementation on OS markers and its related signaling pathways in CRC patients after surgery.

Methods: A total of 76 CRC patients were enrolled and randomized into two groups: the study group (n=39) received Lactobacillus supplementation, while the control group (n=37) received a placebo. The intervention lasted for six months following surgery. Serum levels of catalase (CAT), glutathione (GSH), oxidized glutathione (GSSG), 8-oxo-7,8-dihydro-2′-deoxyguanosine (8-oxodG), and F2-isoprostanes (F2-IsoPs) were measured. In addition, the NRF2/KEAP1, p38 MAPK, and JNK signaling pathways were assessed via western blot analysis.

Results: Following Lactobacillus supplementation, serum CEA levels significantly decreased, whereas CA19-9 levels remained unchanged. OS marker analysis demonstrated increased CAT, GSH, and F2-IsoPs levels and decreased GSSG and 8-oxodG levels in the study group compared to the control group. Western blot results revealed that NRF2, ASK1, MKK3, p-p38, and MKK4 protein levels were significantly reduced after Lactobacillus intervention, while KEAP1 and p-JNK remained unchanged.

Conclusions: Oral administration of Lactobacillus for six months reduced OS marker levels and inhibited NRF2/KEAP1, p38 MAPK, and JNK signaling pathways in CRC patients after surgery. These findings suggest that Lactobacillus may contribute to CRC management by modulating oxidative stress.

Published
2025/05/07
Issue
Vol. 44 No. 7 (2025): Journal of Medical Biochemistry
Section
Original paper

Copyright (c) 2025 Shiru Chen, Weili Ning, Jiye Zhang, Zhenting Wu, Hang Zhou, Ying Liu

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.

Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.